Catherine Manning Adams, MS, MBA

UCB is committed to advancing treatments for rare diseases, with a strong focus on neurology. Dravet syndrome and Lennox-Gastaut syndrome (LGS) are both complex and severe forms of epilepsy, profoundly affecting children and adults. As an advocate, I am dedicated to raising awareness, supporting those impacted, and driving meaningful change in the rare disease community. This work offers a powerful opportunity to improve lives—a cause deeply important to me. By prioritizing patient value in underserved populations, UCB strives to develop innovative solutions where treatment options remain limited.

◾️Oncology, Bladder and Prostate, Immunology and HIV

◾️ Led team to pioneer newly formed Disease Area Stronghold clinical and commercial strategies and platforms to optimize value of localized bladder cancers, non-muscle invasive/muscle invasive, overactive bladder diseases in seven-plus solid tumor portfolio. ◾️ Partner with multiple functional areas, research and development, and business regions to drive strategic/tactical alignment and decision-making with regional commercial stakeholders. Serve as key member on Global Clinical Development Team supporting Phase II and III execution.

◾️ Oversaw asset development and brand strategy across all stages of bladder portfolio. ◾️ Created market engagement with customers, patients, and stakeholders. Drove go/no-go decisions across five-plus programs. ◾️ Managed several oncology products and assets (Balversa®, TARIS®) in multiple indications and rare diseases.

◾️ Led cross-functional launch readiness team and brand creation for CABENUVA first long-acting treatment. ◾️ Established annual marketing plans and promotional tactics focused on desired behavior change and customer experience.

◾️ Reported to President of Infectious Disease and provided transformational HIV leadership to key annual business planning events. ◾️ Established Joint Venture (JV) arrangement to develop combination regimen for HIV patients. ◾️ Built global commercial teams and developed ways of working guidelines between Janssen and ViiV.

◾️ Appointed for special assignment to ensure patient’s voice, patient engagement strategies, and tactics were infused into all therapeutic and functional areas in the Americas (U.S., Canada, South America) market.

◾️ Represented Janssen and Merck to provide holistic management of Immunology/Rheumatology businesses. ◾️ Led account execution to align strategic goals, negotiated ancillary agreements, and guided partnership integration through life of alliance.

Immunology: REMICADE, Simponi and Simponi Aria